Format

Send to

Choose Destination
See comment in PubMed Commons below
Nat Rev Cardiol. 2010 Jan;7(1):48-58. doi: 10.1038/nrcardio.2009.198. Epub 2009 Nov 24.

Cardiovascular effects of relaxin: from basic science to clinical therapy.

Author information

1
Experimental Cardiology Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, Vic 3008, Australia. xiao-jun.du@bakeridi.edu.au

Abstract

Although substantial advances have been achieved in recent decades in the clinical management of heart diseases, new therapies that provide better or additional efficacy with minimal adverse effects are urgently required. Evidence that has accumulated since the 1990s indicates that the peptide hormone relaxin has multiple beneficial actions in the cardiovascular system under pathological conditions and, therefore, holds promise as a novel therapeutic intervention. Clinical trials for heart failure therapy using relaxin revealed several beneficial actions. Here we review findings from mechanistic and applied research in this field, comment on the outcomes of recent phase I/II clinical trails on patients with heart failure, and highlight settings of cardiovascular diseases where relaxin might be effective.

PMID:
19935741
DOI:
10.1038/nrcardio.2009.198
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group
    Loading ...
    Support Center